Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

AIMS: To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine. MATERIALS AND METHODS: Eligible patients had inadequately controlled type 2 diabetes on metformin (≥1500 mg/d) in combination with a dipeptidyl peptidase‐4 (DPP‐4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Roussel, Ronan, Duran‐García, Santiago, Zhang, Yilong, Shah, Suneri, Darmiento, Carolyn, Shankar, R. Ravi, Golm, Gregory T., Lam, Raymond L. H., O'Neill, Edward A., Gantz, Ira, Kaufman, Keith D., Engel, Samuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587501/
https://www.ncbi.nlm.nih.gov/pubmed/30393950
http://dx.doi.org/10.1111/dom.13574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587501/
https://www.ncbi.nlm.nih.gov/pubmed/30393950
http://dx.doi.org/10.1111/dom.13574

Ejemplares similares